TrialClinical drug investigation2013

Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study.

Rajnish Mago et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.